Click a link below to view the mailing archive as if it had been sent to you.
| 2019-12-31 00:15 | | FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer |
| 2019-12-30 12:15 | | FDA clears Eisai’s insomnia drug Dayvigo and more... |
| 2019-12-27 00:15 | | As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis and more... |
| 2019-12-24 12:15 | | Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal |
| 2019-12-24 00:15 | | Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch and more... |
| 2019-12-22 12:15 | | How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition and more... |
| 2019-12-21 00:15 | | Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals and more... |
| 2019-12-20 12:15 | | Will we see the world's first approved NASH drug in 2020? and more... |
| 2019-12-20 00:15 | | Drugmakers rebranding around oncology, rare diseases could provide 2020 preview and more... |
| 2019-12-19 12:15 | | The 4 biggest pharma market access stories of 2019 and more... |
| 2019-12-19 00:15 | | Seattle Genetics, Astellas snag quick FDA approval for bladder cancer-fighter Padcev and more... |
| 2019-12-18 12:15 | | Tune in: Pharma rides audio's surge with podcasts and streaming radio ads and more... |
| 2019-12-18 00:15 | | Good News From the FDA Should Fuel Abiomed’s Growth Into the Future and more... |
| 2019-12-17 12:15 | | All hail drug reps: Most cancer docs rely on pharma salespeople for info, survey finds and more... |
| 2019-12-17 00:15 | | Roche's $4.8B deal for Spark cleared by FTC after long delay and more... |
| 2019-12-16 12:15 | | Novartis axes asthma drug fevipiprant after more trial woes and more... |
| 2019-12-16 00:15 | | The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week and more... |
| 2019-12-15 12:15 | | GSK's ViiV seeks marketing license for baby-friendly HIV pill and more... |
| 2019-12-14 00:15 | | Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion and more... |
| 2019-12-13 12:15 | | Biopharma has abandoned antibiotic development. Here’s why we did, too. and more... |
| 2019-12-13 00:15 | | House passes drug pricing bill that pharma warned would bring 'nuclear winter' and more... |
| 2019-12-12 12:15 | | Gilead's Kite files for FDA approval of second CAR-T therapy and more... |
| 2019-12-12 00:15 | | 4 Trends and Expectations for Drug Delivery in 2020 and more... |
| 2019-12-11 12:15 | | 2 Top Biotech Buyout Candidates and more... |
| 2019-12-11 00:15 | | Leukemia rivals try to stay ahead as Merck, Lilly chase and more... |
| 2019-12-10 12:15 | | Sanofi CEO Hudson backs away from struggling diabetes, cardiovascular areas in strategy unveiling and more... |
| 2019-12-10 00:15 | | Roche extends tender offer for Spark Therapeutics, again and more... |
| 2019-12-09 12:15 | | Merck to acquire ArQule for $20 per share in cash or about $2.7 billion and more... |
| 2019-12-09 00:15 | | 4 FDA Dates Biotech Investors Should Circle in December and more... |
| 2019-12-08 00:15 | | XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B and more... |
| 2019-12-07 00:15 | | Revamped, bipartisan Senate package takes aim at drug prices — and props up other health programs, too and more... |
| 2019-12-06 12:15 | | Alexion shoots down 'proactive' sale demand from activist investor and more... |
| 2019-12-06 00:15 | | After Zantac scare, FDA targets generic metformin for carcinogen tests and more... |
| 2019-12-05 12:15 | | Novartis says mid-stage pipeline is setting up strong growth spurt and more... |
| 2019-12-05 00:15 | | Will sky-high drug prices spur the US to use an obscure power over patents? and more... |
| 2019-12-04 12:15 | | An old, controversial Pfizer drug shows mid-stage efficacy against narcolepsy and more... |
| 2019-12-04 00:15 | | AstraZeneca Sells off Seroquel Rights in U.S. and Canada and more... |
| 2019-12-03 12:15 | | How a New Method is Improving Whole Genome Sequencing of FFPE Tumor Tissues and more... |
| 2019-12-03 00:15 | | Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen and more... |
| 2019-12-02 12:15 | | Merck’s Keytruda gets FDA priority review for high-risk NMIBC and more... |
| 2019-12-01 00:15 | | 5 New Drug Approvals the FDA Gave Top Priority and more... |
